Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Anemia 2beta-Thalassemia 1Thrombocytosis 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

fludarabine phosphate 31Cyclophosphamide 27Mycophenolic Acid 22Whole-Body Irradiation 21Tacrolimus 21ruxolitinib 19Peripheral Blood Stem Cell Transplantation 19Busulfan 19Antilymphocyte Serum 16fludarabine 14Melphalan 12Methotrexate 11Cyclosporine 10thymoglobulin 9Cord Blood Stem Cell Transplantation 7Sirolimus 6Radiotherapy 6Etoposide 6Azacitidine 6Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclosporins 4pomalidomide 3parsaclisib 3Surveys and Questionnaires 3Rituximab 3Prednisone 3Filgrastim 3Cytarabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Primary Myelofibrosis × luspatercept × Clear all
NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Celgene

Phase 2 Completed
95 enrolled 32 charts
Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡